IgM+ and IgM– memory B cells represent heterogeneous populations capable of producing class-switched antibodies and germinal center B cells upon rechallenge with<i>P. yoelii</i>

Brown, Susie L.; Bauer, Jonathan J.; Lee, Juhyung; Ntirandekura, Enatha; Stumhofer, Jason S.

doi:10.1002/jlb.4a0921-523r

Cited by 9 publications

(8 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 C, D) in Py -infected 3H3-treated mice, compared to controls on 90 dpi. Further characterization of these MBCs based on CD73, CD80 and PDL2(14, 15) also revealed that 3H3-treated mice harbored significantly lower numbers of each of these subsets compared to control mice ( Supplemental Fig. 4 A-F ).…”

Section: Resultsmentioning

confidence: 91%

Systemic 4-1BB stimulation augments extrafollicular memory B cell formation and recall responses duringPlasmodiuminfection

Caloba,

Sturtz,

Lyons

et al. 2023

Preprint

View full text Add to dashboard Cite

Clearance of the malarial parasite and protection from reinfection is dependent on T helper cell-dependent germinal center (GC) -derived plasma cells (PC) and memory B cells (MBC). Enhancing or blocking T cell help during experimental malaria has been shown to either improve or impede GC output, respectively. Using a mouse model of malaria, we show that an agonistic antibody against the co-stimulatory molecule, 4-1BB (CD137), hinders an optimal GC response, but enhances humoral immune memory. We demonstrate that this apparent paradox is at least partially driven by CD4 T cell-intrinsic Eomesodermin expression. By using chemoprophylaxis or irradiated parasites we show that the beneficial effects of 4-1BB ligation on humoral immune memory are neither influenced by the inflammatory milieu, nor due to an increased number of MBCs, but rather due to their heightened recall capacity and their ability to readily differentiate into antibody secreting PCs.

show abstract

Section: Resultsmentioning

confidence: 91%

Systemic 4-1BB stimulation augments extrafollicular memory B cell formation and recall responses duringPlasmodiuminfection

Caloba,

Sturtz,

Lyons

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…MBCs are necessary for sustaining long-lasting humoral immunity to pathogenic agents ( 28 ). Previous research has demonstrated that RBD-specific MBCs can survive in a vaccinated person for an extended period of time, up to 1 year ( 29 , 30 ).…”

Section: Discussionmentioning

confidence: 99%

Poor immune response to inactivated COVID-19 vaccine in patients with hypertension

Yang,

Zeng,

et al. 2024

Front. Med.

View full text Add to dashboard Cite

PurposeThe safety and efficacy of vaccination in people with hypertension (HTN) is important. There are currently a few data on the immunogenicity and safety of inactivated SARS-CoV-2 vaccinations in hypertension patients.MethodsAfter receiving a two-dose immunization, 94 hypertension adult patients and 74 healthy controls (HCs) in this study, the evaluation included looking at antibodies (Abs) against receptor binding domain (RBD) IgG, SARS-CoV-2 neutralizing antibodies (NAbs), RBD-specific B cells, and memory B cells (MBCs).ResultsThere was no discernible difference in the overall adverse events (AEs) over the course of 7 or 30 days between HTN patients and HCs. HTN patients had lower frequencies of RBD-specific memory B cells and the seropositivity rates and titers of Abs compared with HCs (all, p < 0.05). HTN patients with cardiovascular and cerebrovascular conditions (CCVD) have lower titers of CoV-2 NAb than in HCs. The titers of both Abs in HTN declined gradually over time.ConclusionInactivated COVID-19 vaccinations were safe in hypertension patients; however humoral immune was limited, especially merged CCVD and declined gradually over time.

show abstract

“…MBCs are necessary for sustaining long-lasting humoral immunity to pathogenic agents [25]. Previous research has demonstrated that RBD-speci c MBCs can survive in a vaccinated person for an extended period of time, up to one year [26,27].…”

Section: Discussionmentioning

confidence: 99%

Poor immune response to inactivated COVID-19 vaccine in patients with hypertension

Zhang

Guo

Yang

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose: The safety and efficacy of vaccination in people with hypertension (HTN) is important. There are currently just a few data on the immunogenicity and safety of inactivated SARS-CoV-2 vaccinations in hypertension patients. Methods: After receiving a two-dose immunization, 94 hypertension patients and 74 healthy controls(HCs) in this study, the evaluation included looking at antibodies(Abs) against receptor binding domain (RBD) IgG, neutralizing antibodies(NAbs), RBD-specific B cells and memory B cells(MBCs). Results: There was no discernible difference in the overall adverse events(AEs) over the course of seven or thirty days between HTN patients and HCs. HTN patients had lower frequencies of RBD-specific memory B cells and the seropositivity rates and titers of Abs compared to HCs(all, p < 0.05). HTN patients may exhibit comparable immunological responses in with or without concomitant cardiovascular and cerebrovascular conditions(CCVD). We again discovered a correlation between a weak Ab response and the interval time following a two-dose immunization. Conclusion: Inactivated COVID-19 vaccinations were safe in hypertension patients, however humoral immune was limited.

show abstract

IgM+ and IgM– memory B cells represent heterogeneous populations capable of producing class-switched antibodies and germinal center B cells upon rechallenge withP. yoelii

Cited by 9 publications

References 79 publications

Systemic 4-1BB stimulation augments extrafollicular memory B cell formation and recall responses duringPlasmodiuminfection

Systemic 4-1BB stimulation augments extrafollicular memory B cell formation and recall responses duringPlasmodiuminfection

Poor immune response to inactivated COVID-19 vaccine in patients with hypertension

Poor immune response to inactivated COVID-19 vaccine in patients with hypertension

Contact Info

Product

Resources

About